Our ASCO 2022 studies find Cellworks TRI predicts survival beyond standard clinical factors
Cellworks Singula™ Therapy Response Index (TRI) Predicts Overall Survival (OS), Disease- Free Survival (DFS) and Tumor Regression Grade (TRG) for Oesophageal Adenocarcinoma: myCare-004
Predictions of Overall Survival (OS) and Progression-Free Survival (PFS) for specific therapeutic interventions in newly diagnosed Glioblastoma Multiforme (GBM) Using Cellworks Singula™: myCare-024-04.
Our ASCO 2022 studies find Cellworks TRI predicts survival beyond standard clinical factors
Select studies from previous ASCO meetings
2021 : Superior overall survival (OS), progression-free survival (PFS), and clinical response (CR) predictions for patients with non-small cell lung cancer (NSCLC) using Cellworks Singula: myCare-022-05.
Model (CBM) to predict therapy response and identify novel biomarkers for 5FU-based combination therapy in gastric cancer patients.
2020 : Superior therapy response predictions for patients with pancreatic cancer (PDAC) using Cellworks Singula: myCare-009-05.
Select studies from previous ASCO meetings
Cellworks Singula™ is a strong predictor of AML treatment outcomes
Therapy Biosimulation Using the
Cellworks Computational Omics Biology
Model (CBM) Is Predictive of Individual
Acute Myeloid Leukemia (AML) Patient
Probability of Clinical Response (CR) and
Overall Survival (OS): myCare-023
Go beyond population-based treatment guidelines
to personalized therapy predictions
POPULATION-BASED
Population-based guidelines treat cancers of the same tissue type as genetically identical and overlook heterogeneity leading to low treatment response rates
PERSONALIZED
Personalized therapy biosimulation predicts the impact of treatments on each patient's unique in silico disease model improving patient outcomes
Go beyond population-based treatment guidelines
to personalized therapy predictions
POPULATION-BASED
Population-based guidelines treat cancers of the same tissue type as genetically identical and overlook heterogeneity leading to low treatment response rates
PERSONALIZED
Personalized therapy biosimulation predicts the impact of treatments on each patient's unique in silico disease model improving patient outcomes
Understand personalized therapy biosimulation
in 30 seconds
See how personalized therapy biosimulation works
on a
patient's multi-gene disease model
Predicting response to treatment with Carboplatin + Pembrolizumab in a NSCLC patient
Predicting response to treatment with Afatinib in a NSCLC patient
Cellworks reports include transparent rationale
for all predictions
SINGULA™
Predicts personalized
response to Standard Care therapies for front-line patients
VENTURA™
Predicts and ranks personalized response to combinations of FDA-approved drugs including off-label and non-oncology drugs for refractory patients
Download Sample Report
Learn about current and upcoming clinical trials
myCare-101
Pan-Cancer
PRINCIPAL INVESTIGATORS
Dr. Tobias Meissner, Avera and
Dr. Scott Howard,
University of Tennessee
PRODUCT
Cellworks Singula™ and Ventura™
myCare-204
AML
PRINCIPAL INVESTIGATORS
Dr. Guido Marcucci and Dr. Anthony Stein,
City of Hope
PRODUCT
Cellworks Singula™
myCare-203
NSCLC
PRINCIPAL INVESTIGATORS
Dr. Mark Klein and Dr. Apar Kishore Ganti,
Veterans Administration
PRODUCT
Cellworks Singula™